Business
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
MOUNTAIN VIEW, Calif., February 26, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced continuing momentum with the Company’s RenovoCath commercial strategy, with new purchase orders received from several esteemed, high volume National Cancer Institute-designated centers.
About this update from Renovorx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/99b9c85bef3d4ae78b255a6109c8eba6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xXBrGI0QfNC7BS3lT4qw6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/99b9c85bef3d4ae78b255a6109c8eba6","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/HRiO7vNxqmLsQM2U4MdcyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/99b9c85bef3d4ae78b255a6109c8eba6","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Initial Revenues Expected this Quarter, and Customer Pipeline for RenovoCath Standalone Device Continues to Expand, Including High Volume National Cancer Institute-Designated Centers","length":182,"tagName":"p","attribs":{}},{"type":"text","content":"RenovoCath Gaining Validation in an Initial U.S. Market Estimated at $400 Million Annually","length":90,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., February 26, 2025--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced continuing momentum with the Company’s RenovoCath commercial strategy, with new purchase orders received from several esteemed, high volume National Cancer Institute-designated centers.","length":485,"tagName":"p"},{"type":"text","content":"Additionally, RenovoRx reported that utilization of RenovoCath devices by its initial customers announced this past December has led to repeat purchase orders. Together, these announcements demonstrate that RenovoRx is continuing on the path to initial revenue generation from RenovoCath sales this quarter and that revenues could begin to ramp during the course of 2025.","length":371,"tagName":"p"},{"type":"text","content":"RenovoRx continues to expand the pipeline of medical institutions that have expressed interest in RenovoCath as a standalone device that addresses high unmet medical needs. RenovoRx expects an average of 5 to 8 annual procedures per patient and pric...